Download PDF
Dtsch Med Wochenschr 2015; 140(16): 1216-1218
DOI: 10.1055/s-0041-103753
Klinischer Fortschritt
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronisches Nierenversagen

Update 2015Chronic kidney disease – update 2015
Christoph Wanner
1   Schwerpunkt Nephrologie, Medizinische Klinik und Poliklinik 1, Universitätsklinikum Würzburg
,
Markus Ketteler
2   Nephrologische Abteilung, Medizinische Klinik III, Klinikum Coburg
› Author Affiliations
Further Information

Publication History

Publication Date:
11 August 2015 (online)

Also available at
   Permissions and Reprints

Schlüsselwörter

Chronische Nierenerkrankung - Diabetische Nephropathie - Seltene Nierenerkrankungen - Prinzipien der Progressionshemmung - Kardiovaskuläre Protektion - Therapiestandards

Keywords

Chronic Kidney Disease (CKD) - Diabetic Nephropathy (DN) - Rare kidney diseases - Principles of slowing progression - Cardiovascular protection - standard of care
 

  • Literatur

  • 1 Green HB, Ethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242
    CrossrefPubMedGoogle Scholar
  • 2 Navaneethan SD, Schold JD, Arrigain S et al. Cause-specific death in non-dialysis-dependent CKD. J Am Soc Nephrol 2015; DOI: 10.1681/ASN.2014101034.
    PubMedGoogle Scholar
  • 3 Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
    CrossrefPubMedGoogle Scholar
  • 4 Schneider MP, Hübner J, Titze S et al. Implementation of the KDIGO Guideline on Lipid Management would require substantial increase in statin prescription rates: an analysis from the GCKD cohort. Kidney Int 2015; in press
    PubMedGoogle Scholar
  • 5 Wanner C, Tonelli M. Lipid management in chronic kidney disease: synopsis of the KDIGO 2013 clinical practice guideline. Kidney Int 2014; 85: 1303-1309
    CrossrefPubMedGoogle Scholar
  • 6 Wanner C, Ketteler M. Chronisches Nierenversagen Update 2014. Dtsch Med Wochenschr 2014; 139: 261-263
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kramer A, Stel SV, Abad Diez JM et al. Renal replacement therapy in Europe – a summary of the 2010 ERA-EDTA Registry Annual Report. Clin Kidney J 2013; 6: 105-115
    PubMedGoogle Scholar
  • 8 Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
    CrossrefPubMedGoogle Scholar
  • 9 De Zeeuw D, Akizawa T, Audhya P et al. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. N Engl J Med 2013; 369: 2492-2503
    CrossrefPubMedGoogle Scholar
  • 10 Devuyst O, Knoers NV, Remuzzi G et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014; 383: 1844-1859
    CrossrefPubMedGoogle Scholar
  • 11 Wühl E, van Stralen KJ, Verrina E et al. Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. Clin J Am Soc Nephrol 2013; 8: 67-74
    CrossrefPubMedGoogle Scholar